Skip to content

Benchmarking Trial Between France and Australia Comparing Management of Primary Rectal Cancer Beyond TME (Total Mesorectum Excision) and Locally Recurrent Rectal Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02551471
Acronym
PELVICARE
Enrollment
165
Registered
2015-09-16
Start date
2015-05-01
Completion date
2018-07-31
Last updated
2018-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Keywords

Locally advanced rectal cancer, Fixed primary rectal cancer, Pelvic recurrence, Benchmarking France Australia

Brief summary

The incidence of rectal cancers is at 15,000 new cases per year in France of which 10 to 15% are locally advanced (T4bNxM0) at the moment of diagnosis. The rate of invaded resection margins (R1) for these locally advanced and fixed rectal tumours varies from 10 to 20%. The invasion of the resection margins triples the risk of local recurrence. In the absence of surgical treatment, the 5-year survival rate for patients having had pelvic recurrence of rectal cancer is lower than 4% whereas it varies from 35 to 40% in cases of curative resection. The care and management of locally advanced and fixed rectal tumours and pelvic recurrence of rectal cancer constitutes, therefore, in the absence of recommendation, a difficult therapeutic problem with great variability in the methods of care and management around the world. These variations in practice can be explained by structural and organizational differences, as well as cultural dissimilarities. With regards to the organization of its healthcare system, Australia is shown to be a leader as regards the care and management of locally advanced and fixed rectal tumours and pelvic recurrence of rectal cancer.

Detailed description

This research project rests on the comparison between two contrasting countries with regards to the care management of PRC-bTME (Primary rectal cancer beyond total mesorectum excision planes) and LRRC (Locally recurrent rectal cancer), France and Australia. Regarding its healthcare system for patients with PRC-bTME and LRRC, Australia equipped itself with a veritable policy of centralisation and clinical pathway, appearing as an international referent country in this surgical field. The main hypotheses of research are that these differences rest on individual and collective representation of disease, organisations, structures, clinical pathway and care management. Benchmarking of clinical practices is a process that consists of a structured comparison and the sharing of good practices of clinical care; it is based on a quality of care assessment and allows to fit into an approach of continuous improvement of this quality of care.

Interventions

OTHERSemi-structured exploratory interviews and focus group with MDT health professional attendees

Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors

OTHERBlinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)

This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries.

OTHERMDT (Multidisciplinary team) meeting observation

3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading).

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients operable and/or capable of receiving a radiotherapy and/or a chemotherapy * Patients in care in the French and Australian centres participating in the study

Exclusion criteria

* Patients suffering from primitive rectal cancer at a stage inferior to T4b * Patients suffering from primitive locally-advanced metastatic rectal cancer (T4NxM1) * Patients suffering from recurrence of metastatic rectal cancer * Patients having been refused a surgical procedure because of one or multiple comorbidities

Design outcomes

Primary

MeasureTime frameDescription
Clinical resection rates in both countries12 monthsExpressed as a percentage and corresponding to the ratio between the number of patients operated and the number of patients discussed in colorectal MDT meetings for PRC-bTME and LRRC. These rates will be expressed separately in each country and compared.

Secondary

MeasureTime frameDescription
R0 resection rate12 monthsExpressed as a percentage and corresponding to the report of the number of patients operated with a surgical resection margin \> 1mm on the number of operated patients
Disease Free Survival12 months
Overall Survival12 months
Concordance rate of operative decisions between France and Australia6 months, 12 monthsAn analysis of concordance between French and Australian operative decisions will be carried out through the radiological (or theoretical) resectability rate, expressed as a percentage and corresponding, after blind inter-country reading of pelvic MRIs, to the ratio between the number of patients judged to have resectable tumours and the number of all MRI re-reading.
Quality of life questionnaire6 months, 12 monthsAccording to MOS SF-36 score and FACT-C score
Stress level score6 months, 12 monthsAccording to distress thermometer (score range from 0 \[no distress\] to 10 \[extreme distress\])
Analyses of semi-structured interviews12 monthsOccurrence and cooccurrence computation of thematic contents (frequency and Chi square analyses) ; similarity analyses (maximum three with connectedness and similarity index computations, identification of the central and peripheral representation cores in each occupational group)
Post-operative morbidity and mortality rates30 daysEvaluated according to the Dindo scale for patients in curative intent treatment. Grade I was any deviation from the normal postoperative course, Grade II included pharmacological treatment, Grade III was complications requiring surgical, endoscopic or radiological intervention, Grade IV included life-threatening complications requiring intensive care unit management and Grade V complications caused postoperative death.

Countries

Australia, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026